AstraZeneca PLC (LON:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

AstraZeneca PLC (LON:AZN) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is £153.33.

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and set a £115 price objective on shares of AstraZeneca in a report on Friday, June 26th. Citigroup cut shares of AstraZeneca to a “buy” rating in a research note on Friday, July 10th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a £180 price target on shares of AstraZeneca in a research report on Friday, June 26th.

AstraZeneca Stock Down 0.3%

AZN opened at £123.40 on Tuesday. The company has a market capitalization of £191.38 billion, a P/E ratio of 18.58, a P/E/G ratio of 0.86 and a beta of 0.23. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The firm’s fifty day moving average price is £135.93 and its two-hundred day moving average price is £140.97. AstraZeneca has a fifty-two week low of £101.98 and a fifty-two week high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.